Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: ztect who wrote (1636)	2/12/1999 12:47:00 AM
From: Katelew	Read Replies (1) \| Respond to of 2135

ZTECH......go back to CBSmarketwatch for more recent commentary on ENMD. In particular, check out the Lehman analyst comments (negative) of the hype surrounding ENMD...the co. is looking more and more like a bit player in this drama. Just trying to help, Daisy

To: ztect who wrote (1636)	2/21/1999 6:11:00 AM
From: Wolff	Read Replies (1) \| Respond to of 2135

Brystol-Myers does not believe the drugs will go to clinical trial. 'At this time, Angiostatin protein in its present form does not meet our criteria for molecules that advance to clinical trials,'' said Robert A. Kramer, Ph.D., vice president, Oncology Drug Discovery for Bristol-Myers Squibb. ''We have chosen to direct our resources to other programs in our broad oncology pipeline. We continue, however, to view antiangiogenesis as an important and viable target in the spectrum of oncology research. Our internal discovery programs that cover a range of antiangiogenesis targets will continue at full strength.'' It was not like staying with ENMD would cost them much, they walked away because they don't believe in the science.